Aprea Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aprea Therapeutics (APRE).

Price Target Range — 11 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingOutperform# Analysts4Avg. Consensus PT$3Upside to Avg. PT+413.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	Ladenburg Thalmann	Kevin DeGeeter	Initiate	Buy	$2
Aug 13, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$6→$3
May 14, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$7→$6
May 7, 2026	Oppenheimer	Matthew Biegler	Initiate	Outperform	$5
Mar 31, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$7
Mar 31, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$4→$1
Feb 10, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$11→$7
Jan 29, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$5→$4
Dec 18, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$20→$5
Jan 15, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
Dec 17, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
Nov 18, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
Oct 24, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
Aug 13, 2024	Wedbush	Robert Driscoll	Maintained	Outperform	$11
Aug 12, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
Jun 24, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
Jun 17, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
May 14, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20
Mar 27, 2024	Wedbush	Robert Driscoll	PT Raise	Outperform	$9→$11
Mar 26, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$20

Analyst Ratings News

PRO
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Buy rating and announces Price Target of $2.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $7 to $6.

Benzinga Newsdesk

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts view APRE, SRFM, CNH stocks.

Avi Kapoor

PRO
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $5.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and maintains $7 price target.

Benzinga Newsdesk

Aprea Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aprea Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PRO
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

People Also Watch

People Also Watch

Aprea Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aprea Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLadenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PROWedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PROWedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PROOppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PROWedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

People Also Watch

People Also Watch

PRO
Ladenburg Thalmann Initiates Coverage On Aprea Therapeutics with Buy Rating, Announces Price Target of $2

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3

PRO
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

PRO
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target